Reasons CDMOs Lose Bioprocessing Bids
Source: ISR Reports
In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes. To learn more, follow the link to the Bioprocessing Trends and Outsourcing Dynamics: 2020-2025 report preview.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more